These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34623361)

  • 1. New ethionamide boosters and EthR2: structural and energetic analysis.
    Vianna JF; Bezerra KS; Lima Costa AH; Barbosa ED; Lima Neto JX; Oliveira JIN; Freire VN; Fulco UL
    Phys Chem Chem Phys; 2021 Oct; 23(40):23233-23241. PubMed ID: 34623361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2.
    Wohlkönig A; Remaut H; Moune M; Tanina A; Meyer F; Desroses M; Steyaert J; Willand N; Baulard AR; Wintjens R
    Biochem Biophys Res Commun; 2017 May; 487(2):403-408. PubMed ID: 28416386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic EthR inhibitors boost antituberculous activity of ethionamide.
    Willand N; Dirié B; Carette X; Bifani P; Singhal A; Desroses M; Leroux F; Willery E; Mathys V; Déprez-Poulain R; Delcroix G; Frénois F; Aumercier M; Locht C; Villeret V; Déprez B; Baulard AR
    Nat Med; 2009 May; 15(5):537-44. PubMed ID: 19412174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator.
    Engohang-Ndong J; Baillat D; Aumercier M; Bellefontaine F; Besra GS; Locht C; Baulard AR
    Mol Microbiol; 2004 Jan; 51(1):175-88. PubMed ID: 14651620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mycobacterium tuberculosis transcriptional repressor EthR is negatively regulated by Serine/Threonine phosphorylation.
    Leiba J; Carrère-Kremer S; Blondiaux N; Dimala MM; Wohlkönig A; Baulard A; Kremer L; Molle V
    Biochem Biophys Res Commun; 2014 Apr; 446(4):1132-8. PubMed ID: 24667600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
    Khan AM; Shawon J; Halim MA
    J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
    Prieri M; Frita R; Probst N; Sournia-Saquet A; Bourotte M; Déprez B; Baulard AR; Willand N
    Eur J Med Chem; 2018 Nov; 159():35-46. PubMed ID: 30268015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
    Nikiforov PO; Blaszczyk M; Surade S; Boshoff HI; Sajid A; Delorme V; Deboosere N; Brodin P; Baulard AR; Barry CE; Blundell TL; Abell C
    ACS Chem Biol; 2017 May; 12(5):1390-1396. PubMed ID: 28314097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2.
    Prevet H; Moune M; Tanina A; Kemmer C; Herledan A; Frita R; Wohlkönig A; Bourotte M; Villemagne B; Leroux F; Gitzinger M; Baulard AR; Déprez B; Wintjens R; Willand N; Flipo M
    Eur J Med Chem; 2019 Apr; 167():426-438. PubMed ID: 30784877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated analysis of ethionamide resistance loci in Mycobacterium tuberculosis clinical isolates.
    da Silva DA; Ferreira NV; Rego AM; Barbosa PCP; Machado RF; Pimentel A; Dos Reis LM; de Pina LC; Redner P; Caldas PCS; Fandinho-Montes FCO; Borga L; Leite SP; da Rocha JL; Bastos LS; Ramos JP; Degrave WM; Antunes LCM; Galvão TC
    Tuberculosis (Edinb); 2018 Dec; 113():163-174. PubMed ID: 30514498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-Based Optimized EthR Inhibitors with
    Villemagne B; Machelart A; Tran NC; Flipo M; Moune M; Leroux F; Piveteau C; Wohlkönig A; Wintjens R; Li X; Gref R; Brodin P; Deprez B; Baulard AR; Willand N
    ACS Infect Dis; 2020 Mar; 6(3):366-378. PubMed ID: 32011115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and docking studies of potent ethionamide boosters.
    Tatum NJ; Villemagne B; Willand N; Deprez B; Liebeschuetz JW; Baulard AR; Pohl E
    Acta Crystallogr C; 2013 Nov; 69(Pt 11):1243-50. PubMed ID: 24192167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
    Flipo M; Desroses M; Lecat-Guillet N; Villemagne B; Blondiaux N; Leroux F; Piveteau C; Mathys V; Flament MP; Siepmann J; Villeret V; Wohlkönig A; Wintjens R; Soror SH; Christophe T; Jeon HK; Locht C; Brodin P; Déprez B; Baulard AR; Willand N
    J Med Chem; 2012 Jan; 55(1):68-83. PubMed ID: 22098589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of the antituberculosis drug ethionamide.
    Vale N; Gomes P; Santos HA
    Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of
    de Welzen L; Eldholm V; Maharaj K; Manson AL; Earl AM; Pym AS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
    Flipo M; Desroses M; Lecat-Guillet N; Dirié B; Carette X; Leroux F; Piveteau C; Demirkaya F; Lens Z; Rucktooa P; Villeret V; Christophe T; Jeon HK; Locht C; Brodin P; Déprez B; Baulard AR; Willand N
    J Med Chem; 2011 Apr; 54(8):2994-3010. PubMed ID: 21417236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
    Vale N; Correia A; Silva S; Figueiredo P; Mäkilä E; Salonen J; Hirvonen J; Pedrosa J; Santos HA; Fraga A
    Bioorg Med Chem Lett; 2017 Feb; 27(3):403-405. PubMed ID: 28057421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
    Nikiforov PO; Surade S; Blaszczyk M; Delorme V; Brodin P; Baulard AR; Blundell TL; Abell C
    Org Biomol Chem; 2016 Feb; 14(7):2318-26. PubMed ID: 26806381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
    Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance.
    Dover LG; Corsino PE; Daniels IR; Cocklin SL; Tatituri V; Besra GS; Fütterer K
    J Mol Biol; 2004 Jul; 340(5):1095-105. PubMed ID: 15236969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.